Unveiling the Social Roots of Undiagnosed Hypertension: A Case Study of a 70-Year-Old Patient

Figures

• 

  Fig. 1. Determining response to tucatinib in a cell line derived and patient derived model of HER2 + breast cancer. BT474 (A) and BCM3472 (B) tumors were treated with tucatinib daily (50 mg/kg via oral gavage). FLT-PET reveals no significant changes in tumor proliferation between BT474 and BCM3472 tumor models (C). FMISO PET (D) and [89Zr]Zr-Pertuzumab PET reveal significant alterations in baseline hypoxia and HER2 expression, respectively

• 

  Fig. 2. [.18F]-FLT PET imaging identifies tucatinib driven changes in tumor proliferation. BT474 tumors were treated with tucatinib and imaged with proliferation FLT-PET imaging (A). FLT-PET reveals significant decreases in proliferation by day 7 (C). Tumors were excised following imaging and stained for Ki-67 to biologically validate changes in proliferation with quantitative IHC analysis (D, E). Results were validated with HER2 + PDX BCM3472 (F–J)

• 

  Fig. 3. [18F]-FMISO PET imaging identifies tucatinib-driven changes in tumor hypoxia. BT474 tumors were treated with tucatinib and imaged with hypoxia-guided FMISO-PET imaging (Fig. 3A). FMISO-PET shows significant reductions in hypoxia by day 7, as measured by FMISO uptake (C). Tumors were excised following imaging and stained for HIF-1α to biologically validate changes in hypoxia with quantitative IHC analysis (D, E). Results were validated in the HER2 + PDX model BCM3472 (F–J)

• 

  Fig. 4. [89Zr]Zr-Pertuzumab PET imaging identifies tumor model dependent changes in HER2 expression following tucatinib therapy. BT474 tumors were treated with tucatinib and imaged with HER2-targeted [89Zr]Zr-pertuzumab PET imaging (A). [89Zr]-Pertuzumab PET reveals significant reductions in HER2 expression by day 14, as measured by PET SUVmean (C). Tumors were excised following imaging and stained for HER2 to biologically validate changes in receptor expression with quantitative IHC analysis (D, E). In contrast, HER2 + PDX BCM3472 tumors did not demonstrate significant changes in [89Zr]Zr-pertuzumab PET uptake or HER2 IHC following tucatinib treatment, despite reductions in tumor volume, indicating HER2 + model-specific differences in HER2 modulation (F–J)